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Abstract
AIM: To study short dsRNA oligonucleotides (siRNA) 
as a potent tool for artificially modulating gene expres-
sion of N-Myc down regulated gene 1 (NDRG1) gene 
induced under different physiological conditions (Nor-
moxia and hypoxia) modulating NDRG1 transcription, 
mRNA stability and translation. 
METHODS: A cell line established from a patient with 
glioblastoma multiforme. Plasmid DNA for transfections 
was prepared with the Endofree Plasmid Maxi kit. From 
plates containing 5 × 107 cells, nuclear extracts were 
prepared according to previous protocols. The pSUPER-
NDRG1 vectors were designed, two sequences were 
selected from the human NDRG1 cDNA (5’-GCATTATT-
GGCATGGGAAC-3’ and 5’-ATGCAGAGTAACGTGGAAG-3’. 
reverse transcription polymerase chain reaction was 
performed using primers designed using published 
information on β-actin and hypoxia-inducible factor 
(HIF)-1α mRNA sequences in GenBank. NDRG1 mRNA 
and protein level expression results under different 
conditions of hypoxia or reoxygenation were compared 
to aerobic control conditions using the Mann-Whitney 
U  test. Reoxygenation values were also compared to 
the NDRG1 levels after 24 h of hypoxia (P  < 0.05 was 
considered significant).
RESULTS: siRNA- and iodoacetate (IAA)-mediated 
downregulation of NDRG1 mRNA and protein expres-
sion in vitro  in human glioblastoma cell lines showed a 
nearly complete inhibition of NDRG1 expression when 
compared to the results obtained due to the inhibitory 
role of glycolysis inhibitor IAA. Hypoxia responsive ele-
ments bound by nuclear HIF-1 in human glioblastoma 
cells in vitro  under different oxygenation conditions 
and the clearly enhanced binding of nuclear extracts 
from glioblastoma cell samples exposed to extreme hy-
poxic conditions confirmed the HIF-1 Western blotting 
results. 
CONCLUSION: NDRG1 represents an additional di-
agnostic marker for brain tumor detection, due to 
the role of hypoxia in regulating this gene, and it can 
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represent a potential target for tumor treatment in hu-
man glioblastoma. The siRNA method can represent an 
elegant alternative to modulate the expression of the 
hypoxia induced NDRG1 gene and can help to monitor 
the development of the cancer disease treatment out-
come through monitoring the expression of this gene 
in the patients undergoing the different therapeutic 
treatment alternatives available nowadays.
© 2012 Baishideng. All rights reserved.
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INTRODUCTION
RNA interference (RNAi) or short dsRNA oligonucle-
otides (siRNA) approach represents a powerful tool for 
drug target discovery and validation in eukaryotic cell 
culture approaches, in vitro, as well as within in vivo sys-
tems, such as animal disease models and human thera-
peutics. siRNA is a potent tool for artificially modulat-
ing gene expression through the introduction of  short 
interfering RNAs. These molecular mechanisms that the 
siRNA approach is consisted of  are occurring naturally 
as a gene regulatory mechanism having a number of  
advantages over other gene/antisense therapies includ-
ing specificity of  inhibition, potency, the small size of  
the molecules and the diminished risk. The systems 
for stable and regulated expression of  these molecules 
emerged as well. Selective gene inhibition via siRNA oc-
curs via two methods: (1) siRNA cytoplasmic delivery 
mimicking an active endogenous RNAi mechanism in-
termediate; and (2) nuclear delivery of  gene expression 
cassettes that express a short hairpin RNA, which mim-
ics the micro interfering RNA active intermediate of  a 
different endogenous RNAi mechanism. In contrast, 
screens of  many siRNA sequences can be accomplished 
rapidly using synthetic oligos. The activity of  siRNA in 
the cytoplasm may lower the barrier and thereby acceler-
ate the successful development of  therapeutics based 
on targeted non-viral delivery systems. Under hypoxia, 
hypoxia-inducible factor (HIF)-1α is involved in the 
transcriptional regulation of  the N-Myc down-regulated 
gene 1 (NDRG1) gene[1,2] (Figure 1) together with other 
transcription factors. In this relation it is of  interest to 
investigate the expression of  NDRG1 protein in human 
cancer[3]. This gene is necessary for P53-mediated apop-
tosis and regulated by phosphatase and tensin homo-
logue. In several cancers, it was suggested to be a tumour 
suppressor gene[4].
MATERIALS AND METHODS
Cell culture, hypoxia treatment and transfection of 
glioblastoma cell lines
Early-passage U373, U251 and U87-MG human malig-
nant glioblastoma from the American Type Culture Col-
lection (ATCC, Rockville, MD, United States) and GaMG, 
a cell line established from a patient with glioblastoma 
multiforme (Gade Institut of  the University Bergen, 
Norway)[5], were grown on glass Petri dishes in Dulbecco’
s modified Eagle’s medium (DMEM) supplemented 
with 10% fetal bovine serum, non-essential amino acids, 
penicillin (100 IU/mL)/streptomycin (100 µg/mL) and 2 
mmol/L L-glutamine. Cells were treated with in vitro hy-
poxia for 1, 6 or 24 h at 5%, 1% or 0.1% O2 as indicated 
in a Ruskinn Invivo2 hypoxic workstation (Cincinnatti, 
OH, United States) as previously described[6,7]. For reoxy-
genation experiments, dishes were returned to the incu-
bator following 24 h of  hypoxia. Plasmid DNA for trans-
fections was prepared with the Endofree Plasmid Maxi 
kit (Qiagen, Hilden, Germany). Stable as well as transient 
transfections were performed using Fugene6 transfection 
reagent (Roche Diagnostics GmbH, Mannheim, Ger-
many) according to the manufacturer’s instructions. The 
pSUPER constructs transfected into U373, U251, U87-
MG and GaMG glioblastoma cells lines were incubated 
for 8 h under standard normoxic conditions (21% O2, 
5% CO2) post transfection with further incubation under 
hypoxic conditions (0.1%) for 24 h.
Preparation of nuclear extracts, whole-cell lysates and 
immunoblotting
From plates containing 5 × 107 cells, nuclear extracts 
were prepared according to previous protocols[8] with 
minor modifications. Aliquots containing nuclear ex-
tracts were stored in aliquots at -80 ℃. Whole-cell lysates 
were prepared with 0.1 mL RIPA buffer (1 × TBS, 1% 
Nonidet P-40) (Amresco, Vienna, Austria), 0.5% sodium 
deoxycholate, 0.1% SDS, protease inhibitors pepstatin 
A (1.4 µmol/L), aprotinin (0.15 µmol/L) and leupeptin 
(2.3 µmol/L), and 100 µmol/L phenylmethylsulfonyl 
fluoride (all were obtained from Sigma, St. Louis, MO, 
United States). To inhibit protein dephosphorylation, 
phosphatase inhibitor mix (Sigma) was added. Using 
a syringe fitted with a 21-gauge needle to shear DNA, 
lysates were transferred to a pre-chilled microcentrifuge 
tube, followed by 30 min incubation on ice. Cell lysates 
were cleared by centrifugation at 15 000 × g for 12 min 
at 4 ℃. Twenty microgram of  whole-cell lysates were 
separated onto SDS 8% polyacrylamide gel electropho-
resis and transferred to a 0.45 µmol/L nitrocellulose 
membrane (Protran BA 85; Schleicher and Schuell, Das-
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sel, Germany). Nonspecific binding was blocked by 5% 
nonfat milk powder in TBS overnight at 4℃ followed by 
incubation with the NDRG1 primary antibody (ab8448, 
Abcam, Cambridge, United Kingdom), diluted 1:1000 
in 2.5% nonfat milk powder in TBS for 1h at room 
temperature or with followed by incubation with the 
M75 mouse monoclonal antibody against CA Ⅸ (Bayer 
Healthcare Co., diluted 1:7200) or with HIF-1?  mono-
clonal antibody (610959, BD Biosciences, dilution 1:500). 
Blots were washed twice in TBS/0.05% Tween-20 (Bio-
Rad, Munich, Germany) and subsequently, three times in 
TBS for (5-10) min each. The secondary antibody goat 
anti rabbit-HRP (stock solution: 400 ?g/mL); DakoCy-
tomation, Denmark) was incubated at a dilution of  1:2000 
for one additional hour at room temperature followed by 
five wash steps as described above. Antibody detection 
and development was as described in[9].
Knock-down of endogenous NDRG1 by siRNA and 
iodoacetate
Human glioblastoma cell lines U373, U251, U87-MG 
and GaMG were grown up to 50% confluence on 10 
cm plates in complete medium (RPMI 1640 medium or 
DMEM depending on the cell line) supplemented with 
10% fetal calf  serum, 100 ?g/mL streptomycin, and 100 
units/mL penicillin). The pSUPER-NDRG1 vectors
were designed as mentioned before[10-17]. To establish 
pSUPER-NDRG1, two sequences were selected from 
the human NDRG1 cDNA (5’-GCATTATTGGCAT-
GGGAAC-3’ (positions 398-416) and 5’-ATGCAGAG-
TAACGTGGAAG-3’ (positions 601 to 619), relative 
to the start codon). All constructs were confirmed by 
sequencing. Transient transfection of  siRNA constructs 
into the glioblastoma brain tumor cell lines exposed to 
extreme hypoxic aeration condition was via Fugene6 so-
lution (Roche, Germany) according to the manufactur-
ers suggested instructions. Also, cells were transfected 
with the empty vector pSUPER (Oligo-Engine, Seattle) 
and pSUPER-NDRG1. Detection of  reduced NDRG1 
mRNA and protein levels was performed by Northern-
blotting and as well as immunoblotting, applying the 
Goat polyclonal anti-NDRG1 antibody (Abcam ab 
21727). Iodoacetate (IAA; 50 ?mol/L) was used as a gly-
colysis inhibitor and was added to the growth medium 
shortly before the respective hypoxia treatment.
Tissue biopsies were obtained surgically from two 
groups of  patients: 15 patients with glioblastoma mul-
tiforme (GBM) and 15 patients with low-grade astrocy-
toma (LGA; WHO grade 2). Samples were immediately 
frozen at -80 ℃ and stored in liquid nitrogen before 
further analysis. To compare the expression of  the indi-
vidual genes examined, reverse transcription polymerase 
chain reaction was performed using primers designed 
using published information on ? -actin and HIF-1?
mRNA sequences in GenBank (accession numbers 
NM_001101 for ? -actin, NM_001530.2 for HIF-1? , and 
NM_006096 for NDRG1, respectively). An aliquot of  
(1-5) ? g of  total mRNA from human gliblastoma and 
astrocytoma tissue or glioblastoma cell lines was tran-
scribed at 42℃ for 1 h in a 20 ?L reaction mixture using 
200 U RevertAid™ M-MuLV RT, oligo(dT)18 primer 
and 40 U Ribonuclease inhibitor (all from Fermentas, 
Ontario, Canada). For polymerase chain reaction (PCR)-
reactions primers were designed in flanking exons with 
Primer3 software (available online http://frodo.wi.mit.
edu/cgi-bin/primer3/primer3_www.cgi): to produce a 
593 bp amplification product of  NDRG1, the forward 
primer (F1) was 5’-CTCTGTTCACGTCACGCTGT-3’ 
and the reverse primer (R1)5’-CTCCACCATCT-
CAGGGTTGT-3’. To produce an 668 bp amplification 
product of  ? -actin, the forward primer (F1) was 5’-CGT-
GCGTGACATTAAGGAGA-3’ (nucleotides 697-716) 
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Figure 1  Hypoxia induced regulation of N-Myc down-regulated gene 1 in human brain cancer hypoxia-inducible factor-1?  induced regulation of hypoxia 
induced N-Myc down-regulated gene 1 expression in human tumour cells. A: Under normoxic oxygenation conditions in the tumor cell microenvironment, hypox-
ia-inducible factor (HIF)-1?  is rapidly degraded via the von Hippel-Lindau tumour suppressor gene product (pVHL)-mediated ubiquitin proteasome pathway; B: When 
the tumor environment aeration conditions shifts from normoxic to hypoxic aeration conditions, HIF-1?  subunit becomes stable, translocates into the cellular nucleus 
and interacts with co-activators of which its transcription machinery is consisted such as p300/CBP to modulate the transcriptional activity of numerous hypoxia induc-
ible genes, like N-Myc down-regulated gene 1 (NDRG1) in the case and about 61 other hypoxia induced genes[28,40]. HRE: Hypoxia response element.
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and the reverse primer (R1) 5’-CACCTTCACCGTTC-
CAGTTT-3’ (nucleotides 1345-1364) and to produce an 
233 bp amplification product of  HIF-1α, the forward 
primer (F1) was 5’-TTACAGCAGCCAGACGATCA-3’ 
(nucleotides 2516–2535) and the reverse primer (R1) 
5’-CCCTGCAGTAGGTTTCTGCT-3’ (nucleotides 
2729-2748). The PCR was performed and PCR products 
were separated on agarose gels as mentioned previously.
Visualisation, expression level evaluation and analysis
The data presented here are representative for 3 similar 
experiments. Densitometric evaluation of  Northern 
blots was performed with 1D Kodak Image Analysis 
Software. Signals were measured in Kodak light units 
and divided by the corresponding signals of  the house 
keeping gene β-actin or 18s RNA for the northern blot 
results. NDRG1 mRNA and Protein level expression 
results under different conditions of  hypoxia or reoxy-
genation were compared to aerobic control conditions 
using the Mann-Whitney U test. Reoxygenation values 
were also compared to the NDRG1 levels after 24 h of  
hypoxia (P < 0.05 was considered significant). Further 
details are outlined in (Figure 2).
RESULTS
Hypoxia induced NDRG1 mRNA in human glioblastoma 
detection via Western blotting
In all four glioblastoma cell lines examined including the 
U373 cell line (Figure 3, upper pannel), expression of  
NDRG1 was either reduced or inhibited upon applica-
tion of  one of  the two siRNA constructs, each separate-
ly showing that the inhibition of  NDRG1 was 100% of  
it basal expression level under normoxic conditions and 
97% from its expression level after hypoxic treatment 
(0.1% O2) for 24 h. Also, when 50 µmol/L of  the gly-
colysis inhibitor IAA was applied, in vitro, for 24 h with 
0.1% hypoxia, on protein level there was an inhibition of  
85% of  the expression level. 
Hypoxia induced NDRG1 mRNA in human glioblastoma 
detection via northern blotting
On mRNA level (Figure 3, lower panel), there was a 
complete inhibition of  NDRG1 mRNA expression also 
when 50 µmol/L glycolysis inhibitor IAA was applied, 
in vitro, for 24 h with 0.1% hypoxia treatment that was 
applied to all glioblastoma cell lines exposed to 0.1% O2 
examined in vitro, showing that the inhibition level on the 
mRNA level is more effective and not depending on the 
nature of  the option applied (Chemical treatment with 
50 µmol/L IAA or the transfection with either NDRG1 
siRNA construct) for NDRG1 down regulation with 
final inhibition of  expressed NDRG1 in glioblastoma 
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Figure 2  Detection and experimental monitoring of hypoxia induced N-Myc 
down-regulated gene 1 in specimens of human brain cancer. The experi-
mental monitoring approach includes (A) experimental approach detection of 
the experimental results. Here, the tumor cell lines are first cultivated in vitro 
and subsequently transfected with the N-Myc down-regulated gene 1 (NDRG1) 
short dsRNA oligonucleotides (siRNA) construct and treated with fixed O2 con-
centration in the hypoxia chamber followed by the specimens extraction, quan-
tification, quality control and molecular seperation of tumor cells specimens. 
Further protein or mRNA blotting and Hybridization with subsequent NDRG1 
expression image detection and documentation take place. The experimental 
approach with these different stages are repeated at least three times to have 
statistical significant results that are necessary for evaluation of the experi-
mental results (B), where first the films with the detected results are scanned 
followed by the detection of the genes expression (which is in the case NDRG1 
gene and the house keeping genes or loading controls (β-actin and 18s RNA, 
respectively) measurement of intensities in the analyzed  specimens, statistical 
analysis and evaluation of the obtained results.
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Figure 3  Inhibition of N-Myc down-regulated gene 1 protein and mRNA 
expression in U373 human glioblastoma cell line in vitro via short dsRNA 
oligonucleotides- and iodoacetate-mediated interference into human 
tumor cellular glycolysis process. Upper panel: Western blotting analysis 
result diagram related to the specific inhibition of hypoxia induced expression 
in human brain tumor cells (U373 Glioblastoma cell line as an example) on 
protein level via Western blotting analysis. Clear complete inhibition of N-Myc 
down-regulated gene 1 (NDRG1) induced by extreme hypoxic conditions in the 
tumor microenviroment (0.1% O2/for 24 h) was present upon transfection with 
the one of the two variants of NDRG1 short dsRNA oligonucleotides (siRNA) 
construct applied in these experiments when compared to the nearly complete 
inhibition via inhibitive interaction with the tumor cell glycolysis pathway. β-actin 
served as a loading control. Figure shows one representative experiment out 
of three experiments; Lower pannel: Northern blotting analysis displaying the 
specific inhibition of hypoxia induced NDRG1 mRNA expression in human brain 
tumor cells (U373 Glioblastoma cell line as an example) on mRNA level. Com-
plete inhibition of NDRG1 induced by extreme hypoxic conditions in the tumor 
microenviroment (0.1% O2/for 24 h) was could be achieved upon transfection 
with the one of the two variants of NDRG1 siRNA construct applied in these 
experiments. Inhibitive interaction into the glycolysis pathway due to the parallel 
treatment with 50 µmol/L with iodoacetate for 24 h showed a similar functional 
effect. The 18s RNA fragment with a molecular weight of 1.9 kb served as a 
loading control. This is one representative experiment out of three experiments.
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cells (Figure 3, lower panel).
Hypoxia induced NDRG1 expression in 2 groups of 
human brain tumour specimens 
In vivo, mRNA expression of  HIF-1α was similar in tu-
mor specimens from patients with low-grade astrocytoma 
or glio-blastoma (results not shown). A tumor-grade as-
sociation with NDRG1 mRNA expression was exhibited 
in vivo. No increase in NDRG1 expression was shown in 
low-grade astrocytoma while an increase of  at least 2-fold 
in NDRG1 expression was shown in 10/15 patients in 
GBM in no patient with LGA as seen in (Figure 4).
DISCUSSION
NDRG1 protein expression has been described to be 
present in normal brain or brain tumor tissue[11] as well 
as being an important gene that is playing an active role 
in the regulation of  a broad spectrum of  human cancer 
diseases like human gastric cancer, squamous cell carci-
nomas, breast cancer, human hepatocellular carcinoma, 
brain tumors and leukemia[12-22]. NDRG1 was suggested 
to be a prognostic marker for hypoxic regions within a 
tumor mass because of  its stability as a protein[23-25] and 
because it is highly expressed in malignant tumor tissues 
compared to normal tissue of  the same origin[26].
During the different sets of  experiments within 
our study, we observed, a brain tumor-type-dependent 
increase in NDRG1 mRNA expression level. NDRG1 
protein and NDRG1 mRNA were generally up-regulated 
in response to prolonged to severe (0.1% O2) in vitro 
hypoxia, although the effect was undetectable at the 
protein level in one cell line with a strong constitutive, 
normoxic NDRG1 expression.
In a previous approach were human tumor speci-
mens from patients suffering from LGA or GBM where 
analyzed showed that tumor specimens with GBM dis-
played a higher level of  NDRG1 than low-grade astrocy-
toma both at the protein and mRNA level[27-29].
As known by previous contributions that induction 
of  NDRG1 sequence-specific posttranscriptional gene 
silencing in different glioblastoma celll lines, in vitro, by 
RNA interference[30,31] resulted in a strong inhibitory 
activity of  NDRG1 expression, both on mRNA and 
protein level. This approach when compared to glycoly-
sis inhibition via IAA application, which has previously 
been shown to posses HIF-1-inhibitory functions[32-36], 
or HIF-1α and hypoxia induced genes like NDRG1 in-
hibitory functions can represent one innovative option 
with a high potential in the monitoring of  human cancer 
disease like brain cancer as shown by the results of  this 
series of  research experiments, since hypoxia-tolerant 
human glioma cells reduce their oxygen consumption 
rate in response to oxygen deficit, a defense mechanism 
that contributes to survival under moderate hypoxic 
conditions[37]. Overcoming the metabolic restrictions of  
hypoxia may allow for the progression of  lower-grade 
tumors to GBM.
An alternative of  this level when used within a frame-
work of  an integrated detection of  monitoring system as 
shown or as it can be seen by the results of  other experi-
mental approaches used to detect different sets of  cancer 
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Figure 4  Expression of N-Myc down-regulated gene 1 mRNA in human brain cancer tissue in vivo. NDRG1: N-Myc down-regulated gene 1; NB: Nonneoplastic 
brain; LGA: Low-grade astrocytoma; GBM: Glioblastoma. 
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disease related genes that are hypoxia induced[11,27-29,35-42] 
can present a therapeutic strategy targeting hypoxia-in-
duced NDRG1. However, the success of  such approach-
es still awaits the development of  an efficient delivery 
system that can affect a large number of  tumor cells.
Experimental inhibition of  NDRG1 expression in 
four glioblastoma cell lines in vitro by either siRNA tech-
nology or interference into tumor cell glycolisis might be 
a potential therapeutic tool in regulating the expression 
of  this gene in glioblastoma. Furthermore, success-
ful inhibition of  tumor cell growth by RNAi aimed at 
oncogenes in vitro and in vivo may represent alternative 
therapeutic applications for these diseases. RNAi is a 
molecular biology tool with a big potential as therapeutic 
agent of  cancer in human.
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Background
N-Myc down-regulated gene 1 (NDRG1) is a member of the NDRG family. Its 
induction occurs via diverse physiological and pathological conditions (hypoxia, 
cellular differentiation, heavy metal, N-myc, neoplasia) which modulate NDRG1 
transcription, mRNA stability and translation.
Research frontiers
Up to this date, the complete detailed function of this protein in humans remains 
unknown. Hypoxia represents a common feature of solid tumors. Hypoxia-
inducible factor-1 (HIF-1) is a key regulator of tumor cell hypoxia. It regulates 
the expression of several genes related to oxygen homeostasis in response to 
hypoxic stress. NDRG1 has been shown to possess more specific characteris-
tics for clinical analysis and identification purposes and has been found to be a 
stable marker of acute tumor hypoxia.
Innovations and breakthroughs
Detailed understanding of how hypoxia regulates transcription of the NDRG1 
gene increase knowledge of the cellular responses of normal and cancer cells 
towards low oxygen tension.
Applications
Direct inhibition of NDRG1 via siRNA or indirect inhibition through interfering with 
the cancer cell glycoltic activities via application of iodoacetate might be a poten-
tial therapeutic tool for regulating the expression of this gene in glioblastoma.
Terminology
Hypoxia is a pathological condition where organ tissues are deprived of ad-
equate oxygen supply due to the failure to deliver oxygen to target tissues. The 
difference between normal oxygen supply and the demand at the cellular level 
may result in an oxygenation hypoxic condition. Normoxia normal oxygen con-
centration as a result of the normal or adequate oxygen supply on the cellular 
level, which is typically 20%-21% O2; Glioblastoma multiforme: Highly invasive 
brain tumors. It is the last stage of human brain tumor where patients suffering 
from this type of brain tumor have a maximum life expectancy of maximum 2-6 
mo. Human glioblastoma multiforme (GBM) cells vary in their ability to survive 
under hypoxic conditions. HIF-1α subunits are highly inducible by different 
oxygenation conditions in human GBM cells, HIF-1 acts as a master regulator 
of numerous hypoxia inducible genes related to angiogenesis, cell prolifera-
tion/survival, and glucose/iron metabolism. Tumor therapy is referring to the 
approaches applied against various cancer diseases in human. They include 
application radiation therapy, surgical removal of cancer tissue, drugs or other 
substances that block the cancer growth and spread by interfering with specific 
molecules involved in tumor growth and progression including medical agents 
that interfere with cell growth signalling or tumor blood vessel development, 
cancer cells specific death promotion, stimulating the immune system to de-
stroy specific cancer cells, and cancer cells toxic chemical agents delivery into 
cancer cells as well as gene therapeutic modalities; Tumor microenvironment: 
Extracellular environment present in a very small region of a solid tumor. It must 
be mentioned that cells in different areas of solid tumors will have markedly dif-
ferent microenvironments; Angiogenesis: The formation of new blood vessels in 
human body tissues.
Peer review
Due to its clear regulatory behaviour under hypoxic condition in human tumor 
cells, NDRG1 represents an additional diagnostic marker for brain tumor detec-
tion. Due to the role of hypoxia in regulating this gene, it can represent a poten-
tial target for tumor treatment in human glioblastoma.
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